Published by:
Hirschfield G, et al. ENHANCE: Safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) - A phase 3 international, randomized, placebo-controlled study. Presented at: The Liver Meeting Digital Experience; Nov. 13-16, 2020.
Read next
VIDEO: Seladelpar safe, well-tolerated in patients with primary biliary cholangitis
Published by:
Hirschfield G, et al. ENHANCE: Safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) - A phase 3 international, randomized, placebo-controlled study. Presented at: The Liver Meeting Digital Experience; Nov. 13-16, 2020.
Click Here to Manage Email Alerts
In this exclusive video, Gideon Hirschfield, FRCP, PhD, from the Toronto Centre for Liver Disease, University of Toronto, discussed results from the ENHANCE study of seladelpar for treating patients with primary biliary cholangitis.
Hirschfield, who is also the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, said seladelpar (CymaBay Therapeutics) was safe and well-tolerated by patients. He reported 10 mg of seladelpar was better than 5 mg and will be further studied in other clinical trials. Additionally, seladelpar significantly reduced pruritis.
Read more about
Click Here to Manage Email Alerts
